DES market share decline prompts Boston update
This article was originally published in Clinica
Executive Summary
Boston Scientific lowered its sales guidance for 2005 at an analyst meeting during the EuroPCR (Paris Course on Revascularisation) conference in Paris this week, indicating that its worldwide market share in drug-eluting stents will probably not be 58-59% as previously expected. Sales of its Taxus DES are now likely to be $2.6-2.8bn for the year, representing a market share of 52-55%. The company said group sales would probably increase by 13-17% to $6.4-6.6bn. Prior predictions were in the range of $6.4-6.7bn.